Revenue: As of FY2025, the actual value is USD 917 K.EPS: As of FY2025, the actual value is USD -1.04.EBIT: As of FY2025, the actual value is USD -30.5 M.<h3>Healthcare Segment</h3><ul><li>Product Revenue: $515 thousand for the year ended July 31, 2025, compared to $0 for the year ended July 31, 2024, primarily due to the inclusion of Cyclo’s revenue following the merger.</li><li>General and Administrative Expenses: Increased to $13.2 million from $8.3 million, primarily due to Cyclo’s consolidation and increased legal fees related to the merger.</li><li>Research and Development Expenses: Increased to $12.6 million from $3.7 million, mainly due to Cyclo’s consolidation.</li><li>Loss from Operations: $25.3 million, a decrease from $102 million, reflecting the absence of in-process research and development expenses from the previous year.</li></ul><h3>Infusion Technology Segment</h3><ul><li>Revenue: $93 thousand, down from $355 thousand, reflecting reduced operations.</li><li>Loss on Impairment of Goodwill: $3.1 million impairment charge recorded due to operational reductions.</li><li>Loss from Operations: $3.8 million, up from $675 thousand, primarily due to goodwill impairment.</li></ul><h3>Real Estate Segment</h3><ul><li>Rental Revenue: Increased to $309 thousand from $282 thousand, with third-party rental revenue increasing by 13%.</li><li>General and Administrative Expenses: Increased to $296 thousand from $142 thousand, due to higher legal and operating expenses.</li><li>Income (Loss) from Operations: Loss of $50 thousand compared to income of $80 thousand, reflecting increased expenses.</li></ul><h3>Outlook / Guidance</h3>The company expects the balance of cash and cash equivalents to be sufficient to meet obligations for at least the next 12 months from the filing of this Annual Report.

Rafael-B | 10-K: FY2025 Revenue: USD 917 K